Drug intelligence / Profile preview

MVD-1 analog

Development stage: Preclinical
Lead developer: Eolo Pharma
Modality: Small Molecules
Administration: Oral

Overview

MVD-1 analog is a small molecule, oral thermogenic new chemical entity (NCE) currently in the discovery and characterization phase at Eolo Pharma. It is being developed as a follow-on compound to the company's lead asset, MVD-1, for the treatment of metabolic and cardiovascular conditions, including obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH), and hypertension. The drug is designed to stimulate energy expenditure by activating thermogenic processes in adipose tissue, potentially through the browning of white adipose tissue and the activation of brown adipose tissue. As a next-generation analog, it aims to optimize the pharmacological profile of the MVD series for chronic metabolic management.

Beyond the preview

Go deeper on MVD-1 analog.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVD-1 analog.

Explore the full profile